TIDES USA Oligonucleotide & Peptide Therapeutics 2025

 Include: 3 videos + 1 pdf, size: 33.69 GB

Target Audience: professionals in drug discovery, who focus on oligonucleotide, peptide, mRNA, and genome editing therapeutics

 Information:

A translational, end-to-end program covering discovery, delivery, CMC, analytics, manufacturing, and clinical development for oligonucleotide and peptide drugs. Sessions convert cutting-edge science into practical playbooks for moving candidates efficiently from idea to IND and through the clinic.

What You Will Learn

• Platform selection & design: ASO/siRNA/miRNA/mRNA/saRNA vs. peptides/peptidomimetics—chemistries, stability, and manufacturability

• Delivery strategies: LNPs, GALNAc, conjugates, depot and targeted systems; PK/PD and biodistribution considerations

• CMC & analytics: impurity control, sequence confirmation, potency/stability assays, comparability, and QbD

• Process development & scale-up: solid-phase/liquid-phase synthesis, hybrid approaches, purification and formulation

• Regulatory & quality: IND/IMPD expectations, ICH alignment, control strategies, and lifecycle management

• Nonclinical & clinical translation: models, safety/pharm-tox, biomarkers, dose selection, trial design

• Operations: raw-material sourcing, supply chain resilience, technology transfer, and cost-of-goods levers

• Data & digital: sequence optimization, structure prediction, in-silico off-target analysis, and AI/automation in analytics

Event Details

• Format: Plenary talks, parallel technical tracks, case studies, panels, posters, and exhibits

• Structure: Discovery/design → Delivery/PKPD → CMC/analytics → Manufacturing/scale-up → Clinical/regulatory → Commercialization

• Takeaways: Checklists, templates, and benchmark metrics for immediate team adoption

Who Should Attend
R&D scientists, CMC and QA/QC leaders, process/analytical chemists, formulation and delivery engineers, clinical and regulatory teams, manufacturing/operations managers, BD and strategy leaders, platform founders, and investors.

Why Attend

• Replace trial-and-error with validated development pathways for RNA and peptide modalities

• Anticipate regulatory and manufacturing pitfalls early to de-risk timelines and budgets

• Build partnerships across discovery, CMC, and clinical teams to accelerate to proof-of-concept